Current Advanced Statistical Issues in Clinical Research—Adaptive Designs and Translational Medicine  by Hsiao, Chin-Fu et al.
J Formos Med Assoc | 2008 • Vol 107 • No 12 Suppl S1
Recently, with the availability of genomic techno-
logies and other new science, the biotechnology
and pharmaceutical industries have attracted much
global attention. However pharmaceutical devel-
opment is a risky, complex, costly, and time-
consuming endeavor. It usually takes more than
12 years with an average cost between 800 mil-
lion and one billion US dollars to develop a drug
from screening of candidates to regulatory ap-
proval for commercial marketing. A hefty 70% of
the cost for pharmaceutical development is wasted
on drugs that do not even make it to market. In
addition, more than half of the development du-
ration is spent in clinical trials. Despite better un-
derstanding of disease etiology, a rapid increase
in resources, technological advances, seemingly
great number of potential candidates and a longer
development duration, the performance of drug
development is disappointing. In fact, only one
out of 10,000 candidates screened in the labora-
tory will survive to the market launch. More than
60% of the potential candidates that enter into
clinical development fail. Furthermore, the success
rate of the phase III stage of clinical development
has fallen by 30%. As a result, the total duration
of drug development is increased.
The latest advanced high-throughput technol-
ogy is generating a far greater number of poten-
tial drug candidates than before to reach clinical
development. But the success rate of drug regis-
tration has declined drastically in recent years.
One of the many possible reasons for the unsatis-
factory performance is that the current paradigm
for drug development is no longer functioning for
the 21st century. Therefore, new concepts, strategies,
and methodology are urgently needed to reduce
the development cost, to shorten the develop-
ment duration, and to improve the development
success rate. In recent years, the use of adaptive
design methods in clinical research and develop-
ment based on accrued data has become very
popular due to its flexibility and efficiency. In
clinical trials, it is not uncommon to modify trial
and/or statistical procedures during the conduct
of clinical trials based on the review of interim
data. The purpose is not only to efficiently identify
the clinical benefits of the test treatment under
investigation and save time and money, but also
to increase the probability of success of clinical
development. As a result, adaptive designs seem
to open a whole new territory for drug develop-
ment and represent an opportunity to gain dra-
matic efficiencies during the drug development
process.
In recent years, how to apply basic research
discoveries to the development of trials and studies
in humans has attracted much attention. Such
basic research is typically conducted in the labo-
ratory, or in preclinical studies in which scientists
study disease at a molecular or cellular level.
Translational medicine refers to the translation of
basic scientific discoveries into practical applica-
tions. More specifically, translational research
moves basic discoveries from the laboratory
(“the bench”) into clinical practice to diagnose
and treat patients (“bedside”). Under this new
approach, basic scientists can offer clinicians new
tools for use in patients, and clinicians can gain
more insight about the nature and progression of
disease to motivate basic research. Translational
medicine incorporates aspects of both basic science
and clinical research, and consequently forms a
powerful practice that accelerates clinical research.
Both adaptive designs and translational med-
icine research play important roles in a scientific
manner to pharmaceutical research. However,
the statistical work to draw a statistical inference
with regard to translational medicine research is
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still in a preliminary stage. On the other hand,
although there are many adaptive design methods
available, how adaptive design can be optimized
remains a critical issue.
To aid comprehensive understanding of the
statistical designs and methodology that are com-
monly employed in adaptive designs and trans-
lational research, and with the support of the
Bureau of Pharmaceutical Affairs, Department of
Health, Taiwan, the National Health Research
Institutes and Formosa Cancer Foundation or-
ganized two symposiums on “Current Advanced
Statistical Issues in Clinical Trials—Adaptive
Designs”, held on November 25, 2006, and
“Current Advances in Evaluation of Research and
Development of Translational Medicine”, held
on October 19, 2007, in Taipei, Taiwan. Both sym-
posiums attracted more than 400 participants and
received important research attention in Taiwan.
In celebration of this success, this special issue of
the Journal of the Formosan Medical Association,
“Current Advanced Statistical Issues in Clinical
Research—Adaptive Designs and Translational
Medicine” includes 10 works that were presented
at the two symposiums. Through this special issue,
we hope that readers will more fully understand
the statistical issues surrounding adaptive designs
and translational medicine.
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